Table 1.
Demographic, biochemical and histology characteristics of participants.
| Baseline (n = 50) | Week 24 (n =45) | |
|---|---|---|
| Demographics | ||
| Female participants | 31 (62%) | 29 (64%) |
| Age (years) | 49.3 ± 14.2 | |
| Waist (cm) | 106.4 ± 11.3 | 107.4 ± 12.2 |
| Hip (cm) | 111.7 ± 9.1 | 113.7 ± 10.1 |
| Height (m) | 1.7 ± 0.1 | 1.7 ± 0.1 |
| Weight (kg) | 93.0 ± 18.3 | 92.4 ± 19.1 |
| BMI (kg/m2) | 33.4 ± 5.1 | 33.5 ± 5.3 |
| Race and Ethnicity | ||
| White (vs. non-White) | 40 (82%) | 36 (82%) |
| Hispanic (vs. non-Hispanic) | 17 (34%) | 16 (36%) |
| Diabetes | 14 (28%) | 14 (31%) |
| Biochemical profile | ||
| AST (IU/L) | 32.5 (28.0) | 32.0 (31.0) |
| ALT (IU/L) | 47.5 (30.0) | 43.0 (34.0) |
| Alk Phos | 72.0 (31.0) | 73.0 (44.0) |
| GGT (U/L) | 40.0 (37.0) | 40.5 (31.5) |
| Total bilirubin (mg/dL) | 0.5 (0.3) | 0.4 (0.2) |
| Direct bilirubin (mg/dL) | 0.1 (0.1) | 0.1 (0.1) |
| Albumin (g/dL) | 4.5 (0.4) | 4.5 (0.3) |
| Glucose (mg/dL) | 104.5 (40.0) | 102.0 (21.0) |
| HgA1c (%) | 5.9 (0.9) | 6.0 (0.8) |
| Insulin | 24.0 (19.0) | 29.0 (19.0) |
| Total cholesterol (mg/dL) | 180.5 (38.0) | 166.0 (48.5) |
| Triglycerides (mg/dL) | 150.5 (77.0) | 130.5 (68.5) |
| HDL (mg/dL) | 44.5 (17.0) | 48.5 (17.0) |
| LDL (mg/dL) | 94.0 (38.0) | 80.0 (33.0) |
| Histology | ||
| Steatosis | ||
| 1 | 14 (28.0%) | 14 (40.0%) |
| 2 | 13 (26.0%) | 13 (37.1%) |
| 3 | 23 (46.0%) | 8 (22.9%) |
| Median (IQR) | 2.0 (2.0) | 2.0 (1.0) |
| Lobular inflammation | ||
| 1 | 21 (42.0%) | 14 (40.0%) |
| 2 | 29 (58.0%) | 20 (57.1%) |
| 3 | -- | 1 (2.9) |
| Median (IQR) | 2.0 (1.0) | 2.0 (1.0) |
| Ballooning | ||
| 0 | 4 (8.0%) | 6 (17.1%) |
| 1 | 29 (58.0%) | 19 (4.3%) |
| 2 | 17 (34.0%) | 10 (28.6%) |
| Median (IQR) | 1.0 (1.0) | 1.0 (1.0) |
| Fibrosis | ||
| 0 | 15 (30.0%) | 11 (31.4%) |
| 1 | 16 (32.0%) | 9 (25.7%) |
| 2 | 7 (14.0%) | 4 (11.4%) |
| 3 | 10 (20.0%) | 10 (28.6%) |
| 4 | 2 (4.0%) | 1 (2.9%) |
| Median (IQR) | 1.0 (2.0) | 1.0 (3.0) |
| NAS | ||
| 2 | -- | 4 (11.4%) |
| 3 | 4 (8.0%) | 3 (8.6%) |
| 4 | 14 (28.0%) | 9 (25.7%) |
| 5 | 14 (28.0%) | 9 (25.7%) |
| 6 | 11 (22.0%) | 9 (25.7%) |
| 7 | 7 (14.0%) | 1 (2.9%) |
| Median (IQR) | 5.0 (2.0) | 5.0 (2.0) |
| Imaging | ||
| MRI-PDFF (%) | 16.6 (12.8) | 12.9 (9.9) |
| TLV (mL) (N=45) | 1768.4 (540.7) | 1733.6 (657.9) |
| TLFI (% mL) (N=45) | 285.3 (346.3) | 227.5 (291.6) |
| MRI-PDFF (%) | 17.1 ± 8.4 | 13.9 ± 6.9 |
| TLV (mL) (N=45) | 1836.0 ± 514.9 | 1815.7 ± 493.9 |
| TLFI (% mL) (N=45) | 325.9 ± 210.9 | 268.9 ± 176.1 |
Mean ± standard deviations presented above for normally distributed variables, median (interquartile range) for non-normally distributed variables. N (%) for categorical variables.
Abbreviations: AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; BMI, Body Mass Index; CACs, coronary artery calcium score; FRS, Framingham risk score; HDL, High-Density Lipoprotein; Hgb A1C, hemoglobin A1C; LDL, Low-Density Lipoprotein; Alk Phos, Alkaline Phosphatase; GGT, Gamma- Glutamyl Transferase; MRI-PDFF, magnetic resonance imaging proton-derived fat fraction; NAS, NAFLD Activity Score; TLV, total liver volume; TLFI, total liver fat index.